← Back to Search

Monoclonal Antibodies

Pembrolizumab for Lung Cancer

Phase 1

Waitlist Available

Led By Siqing Fu, MD, PhD

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 1 year

Awards & highlights

Study Summary

This trial is testing a new drug combination to see if it is effective and safe in treating people with metastatic solid tumors.

Eligible Conditions

Lung Cancer
Breast Cancer
Pancreatic Cancer
Tumors
Ovarian Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To establish the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) ZN-c3 and bevacizumab.

To establish the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of ZN-c3 .

Side effects data

From 2024 Phase 2 trial • 57 Patients • NCT03004183

21%

Fatigue

13%

Nausea

11%

Back pain

Shortness of Breath

Anemia

Abdominal pain

Diarrhea

Pneumonia

Kidney Injury and/or Infection

Dyspnea

Weight Loss

Malnutrition, Hypercalcemia and Weakness

Pneumothorax

Intractable pain, back pain, hip pain

Activated partial thromboplastin time prolonged

Pleural effusion

Atrial fibrillation with rapid ventricular response

Thrombocytopenia

Respiratory failure

Skin rash

colitis

100%

80%

60%

40%

20%

Study treatment Arm

Single Arm

Trial Design

2Treatment groups

Experimental Treatment

Group I: Regimen BExperimental Treatment3 Interventions

ZN-c3 in combination with bevacizumab and pembrolizumab

Group II: Regimen AExperimental Treatment2 Interventions

ZN-c3 in combination with bevacizumab

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Bevacizumab

FDA approved

Pembrolizumab

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor

2,972 Previous Clinical Trials

1,787,299 Total Patients Enrolled

Zentalis PharmaceuticalsUNKNOWN

1 Previous Clinical Trials

78 Total Patients Enrolled

Siqing Fu, MD, PhDPrincipal InvestigatorM.D. Anderson Cancer Center

2 Previous Clinical Trials

147 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any deleterious effects associated with Pembrolizumab?

"Since Pembrolizumab is in the early stages of clinical trials, its safety has been prospectively assessed as a 1 due to scant data concerning efficacy and security."

Answered by AI

Is recruitment for this trial still ongoing?

"According to records found on clinicaltrials.gov, this particular medical study is no longer recruiting participants; the trial was originally listed December 30th 2022 and last modified August 31st 2022. Nevertheless, 2431 other trials are actively looking for volunteers at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

2022. "Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05431582.